Trial Profile

A Phase II Evaluation of ABT-888 (IND 77840, NCI Supplied Agent: ABT-888, NSC 737664), Topotecan (NSC 609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Veliparib (Primary) ; Filgrastim; Pegfilgrastim; Topotecan
Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use

25 Mar 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
13 Jul 2013 New source identified and integrated (M.D. Anderson Cancer Center; GOG0127W).
11 Mar 2013 Status changed from recruiting to suspended as reported by clinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com